NSAID-exacerbated respiratory disease (N-ERD) is a chronic eosinophilic, inflammatory disorder of the respiratory tract occurring in patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP), symptoms of which are exacerbated by NSAIDs, including aspirin. Despite some progress in understanding of the Abbreviations: ASA, acetylsalicylic acid; ATAD, aspirin treatment after desensitization; COX, cyclooxygenase; CRSsNP, chronic rhinosinusitis without nasal polyps; CRSwNP, chronic rhinosinusitis with nasal polyps; LTMD, leukotriene-modifying drugs; N-ERD, NSAID-exacerbated respiratory disease; NSAIDs, non-steroidal anti-inflammatory drugs.
pathophysiology of the syndrome, which affects 1/10 of patients with asthma and rhinosinusitis, it remains a diagnostic and therapeutic challenge. In order to provide evidence-based recommendations for the diagnosis and management of N-ERD, a panel of international experts was called by the EAACI Asthma Section. The document summarizes current knowledge on the pathophysiology and clinical presentation of N-ERD pointing at significant heterogeneity of this syndrome. Critically evaluating the usefulness of diagnostic tools available, the paper offers practical algorithm for the diagnosis of N-ERD. Recommendations for the most effective management of a patient with N-ERD stressing the potential high morbidity and severity of the underlying asthma and rhinosinusitis are discussed and proposed.
Newly described sub-phenotypes and emerging sub-endotypes of N-ERD are potentially relevant for new and more specific (eg, biological) treatment modalities. Finally, the document defines major gaps in our knowledge on N-ERD and unmet needs, which should be addressed in the future.
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| INTRODUCTION

NSAID-exacerbated respiratory disease (N-ERD), originally referred
to as aspirin-induced asthma, is a clinical syndrome that typically includes hypersensitivity to aspirin and other non-steroidal antiinflammatory drugs (NSAIDs), nasal polyposis, and asthma. It was clinically described by Samter and Beers 1 fifty years ago, and its non-allergic pathomechanisms were elucidated by Andrew Szczeklik in 1975, 2 but it still remains a diagnostic and therapeutic challenge.
N-ERD affects approximately 1/10 of adults with asthma or with chronic rhinosinusitis and nasal polyps. 3 From the allergist's perspective, it is a specific type of NSAID hypersensitivity, from the perspective of the respiratory physician, it represents a phenotype of difficult to treat asthma, and for the ENT surgeon, the recurrent nasal polyposis typical for N-ERD is a difficult challenge. 3, 4 Despite the morbidity from the syndrome and its relatively high prevalence, the initial cause and the underlying mechanisms remain incompletely explained. In order to provide evidence-based recommendations for the diagnosis and management of on N-ERD, a panel of experts was called by the EAACI Asthma Section and included also representatives of the EAACI ENT and Drug Hypersensitivity Section. In addition, internationally renowned experts, representing the non-European perspective on N-ERD, have been invited to the panel.
| Nomenclature and definitions
The panel of experts endorses EAACI recommendations 5 that the term "NSAID" is a more inclusive term to replace "aspirin" in descriptions of this subtype of hypersensitivity to drugs that inhibit cyclooxygenase. Accordingly, it is recommended that NSAIDs-exacerbated respiratory disease (abbreviated as N-ERD) is a more proper term to describe the syndrome of respiratory hypersensitivity to NSAIDs associated with asthma and chronic rhinosinusitis with nasal polyposis. Previously used names (e.g, aspirin-exacerbated respiratory disease, aspirin-induced asthma, and aspirin triad) should be abandoned.
BOX 1 Definitions and abbreviations
• NSAID-exacerbated respiratory disease (N-ERD) is a chronic eosinophilic inflammatory disorder of the respiratory tract occurring in patients with asthma and/or rhinosinusitis with nasal polyps, which symptoms are exacerbated by NSAIDs, including aspirin.
• NSAID challenge (NC) is an in vivo diagnostic procedure used to confirm or exclude suspected hypersensitivity to a culprit drug.
• NSAID Tolerance Test (NTT) is an in vivo diagnostic procedure used to confirm patient's oral tolerance to alternative NSAID.
• Aspirin desensitization (AD) is a procedure when tolerance of aspirin is induced in a hypersensitive patient by increasing doses of aspirin given orally or intranasally in short time intervals. The term aspirin desensitization should not apply to chronic treatment with aspirin after the tolerance has been achieved.
• Aspirin Treatment After Desensitization (ATAD) is a therapeutic (usually long-lasting) procedure when aspirin is given orally or intranasally after the tolerance has been achieved during aspirin desensitization procedure.
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Definitions used in this document and recommended for use with respect to the N-ERD are listed in Box 1.
| Methods-search strategy
Evidence for the recommendations was collected by electronic literature searches of the MEDLINE and EMBASE databases, using these primary key words: NSAID-exacerbated respiratory disease, aspirinexacerbated respiratory disease, aspirin-sensitive asthma, aspirininduced asthma, Samter's triad, aspirin triad, and Widal's triad, with extra key words as appropriate for each specific section. Each article was reviewed for suitability and the recommendations were evidence graded by two members of the panel using the SIGN criteria.
Where evidence was lacking, during the panel meetings a consensus was reached among the experts.
| PREVALENCE AND RISK FACTORS
The prevalence of N-ERD is unknown and varies from 1.8% to 44%, depending on the population and diagnostic criteria used. Respiratory symptoms following NSAID intake have been reported by 1.8%
of the general European population and by 10%-20% of patients with asthma. 6, 7 A recent meta-analysis concluded that N-ERD has been diagnosed among 5.5% to 12.4% of adult asthmatics (the mean prevalence, 7.1%), but the prevalence rises to 21% when NSAID hypersensitivity is determined by provocation. 6, 8 The prevalence of N-ERD increases with the severity of the underlying airway disease, reaching 14.9% among patients with severe asthma 3 and up to 24%
in patients admitted to the intensive care unit (ICU) with an asthma exacerbation. 9 Risk factors include family history of N-ERD, presence of CRSwNP, and/or asthma. In contrast to earlier reports, recent studies show a high prevalence of atopy among N-ERD patients.
10,11
3 | CLINICAL PRESENTATION OF N -ERD
| Acute reaction to NSAIDs
In patients with N-ERD, the clinical reaction to aspirin or other NSAID is manifested by upper and/or lower airway symptoms, which develop within 30-180 min. The reaction usually starts with nasal congestion and/or rhinorrhea, followed by wheezing, coughing, and shortness of breath. In patients with unstable asthma, the symptoms may appear much faster, progressing rapidly to severe bronchospasm or even leading to death. 12 A subgroup of N-ERD patients will develop pronounced flushing, urticarial, and/or gastrointestinal symptoms. 13 Both the onset and severity of the reaction, in a given patient, are dose-related and the lowest dose provoking a reaction (threshold dose) for individual patients varies between 10 and 300 mg, but 60 mg of ASA would induce symptoms in a majority of patients.
14,15 is approximately twice the general asthma population. 17 In the ENFU-MOSA study, a history of aspirin hypersensitivity emerged as an independent risk factor for severe asthma. 18 In an European cohort, 51% of patients with NSAID hypersensitivity were on inhaled and oral corti- and loss of smell may be considered a clinical marker to identify N-ERD patients. 20 On average, upper respiratory symptoms are worse, and recurrence of nasal polyps after surgery is more frequent in N-ERD than in NSAIDs-tolerant CRSwNP patients.
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Rhinoscopy or nasal endoscopy findings of edema/mucosal obstruction, and or nasal polyps, and/or mucopurulent discharge, primarily from the middle meatus, are usually present in N-ERD patients helping to the diagnosis of CRS. 21, 22 On a upper CT scan, which is the gold standard for imaging, N-ERD patients have a more severe sinus opacification and extension than CRSwNP patients without N-ERD. way inflammation in N-ERD patients has also been suggested. 31 Contribution of genetic and epigenetic polymorphisms has been also investigated suggesting a permissive, genetic predisposition for N- 37 Significant differences between groups were found in the serum total IgE levels, eosinophil counts, and urinary LTE 4 levels.
Another study reported a group of patients with asthma and rhinitis, who presented with respiratory reactions to a single NSAID (including paracetamol) and good tolerance to aspirin. 38 Similarly, heterogeneity of N-ERD phenotypes has also been reported among children with N-ERD with 32% of the cases presenting with a combination of respiratory and cutaneous symptoms after aspirin challenge. 39 These studies document a wider than currently appreciated spectrum of N-ERD phenotypes and/or presence of sub-phenotypes, pointing at the necessity for re-evaluation of clinical criteria for the diagnosis of N-ERD. Furthermore, heterogeneity of the underlying pathophysiological mechanism (presence of sub-endotypes) may have critical implications for the development of sub-endotype-specific treatment approaches, potentially increasing the effectiveness of aspirin treatment after desensitization (ATAD), treatment with leukotriene modifiers or biologicals in patients with N-ERD.
| DIAGNOSIS
A clear history of multiple reactions developed within 1-2 hours after ingestion of an NSAID manifesting with respiratory symptoms in a patient with adult-onset asthma and recurrent nasal polyposis may be sufficient to diagnose N-ERD. However, the reliance exclusively on a history may result in either underdiagnosing or overdiagnosing of NSAIDs hypersensitivity. 40, 41 In certain cases, a challenge test with aspirin or culprit drug is necessary to establish the diagnosis.
Statements and recommendations [41] [42] [43] [44] [45] [46] [47] • N-ERD should be considered in patients suffering from asthma and chronic rhinosinusitis whose symptoms exacerbate after ingestion of aspirin and other COX-1 inhibitors (Grade 4 D).
• Lack of history of respiratory reactions to NSAIDs in a patient with asthma and CRS with nasal polyposis does not exclude the presence of hypersensitivity (Grade 3 C).
• • Challenge tests with aspirin should be performed only according to established indications (Grade 4 D). (Table 2) • Oral aspirin challenge is considered to be the gold standard for diagnosing hypersensitivity to NSAIDs, as it mimics natural exposure to the drug (Grade 4 C).
• Inhalation challenge with lysine-aspirin is as sensitive as oral one (Grade 3 C), but safer and faster to perform (Grade 4 C)
• Intranasal aspirin challenge, although less sensitive when compared with oral (Grade 3 C), is safer, quicker and may be a good diagnostic alternative for patients in whom oral or inhaled challenge is contraindicated (Grade 4 D)
• Intranasal aspirin challenge can be used initially to diagnose the most sensitive subjects safely, leaving the less sensitive ones to be challenged orally (Grade 3 C)
• Intranasal challenge with ketorolac is less sensitive and cannot substitute for oral aspirin challenge (Grade 3 C)
• • diagnosis of hypersensitivity to NSAIDs • research purposes.
Indications for intranasal aspirin challenge:
• diagnosis of hypersensitivity to NSAIDs in patients with contraindications to oral or inhalation tests
• diagnosis of N-ERD in patients with upper airways symptoms of hypersensitivity to NSAIDs
• research purposes.
• Oral and inhalation tests should be performed in a specialized clinical setting (either outpatient or hospital) by experienced physicians and trained nurses. After completion of the test, the patient should stay in the office for few hours to one day, depending on clinical assessment (e.g, severity of the reaction) (Grade 4 D).
• Several protocols for aspirin challenges can be used and Table 2 describes the protocol recommended by the panel.
• In vitro tests that have been proposed to confirm aspirin hypersensitivity (e.g, sulfidoleukotrienes release assay; 15-HETE generation assay (ASPITest); or basophil activation test (BAT)) cannot substitute for aspirin challenges and are not recommended for routine diagnosis (GRADE 3 C).
| Algorithm for diagnosis of N-ERD
N-ERD should be suspected if a patient reports respiratory symptoms occurring after ingestion of aspirin or other NSAIDs. The following algorithm for diagnosis of N-ERD is recommended by the panel (Figure 2 ).
Step 1 Ask about respiratory symptoms after intake of any NSAID, including aspirin.
Step 2. Verify if the reported history of NSAID-induced respiratory reaction is reliable. The reliability increases if, for example more than one reaction occurred, reactions to two or more different NSAIDs have been reported or the latest reaction occurred within last 5 years. Note that respiratory symptoms may be accompanied by skin and gastrointestinal symptoms.
Step 3. Ask about underlying chronic respiratory disorders (CRS with NP and/or asthma). The following clinical characteristics increase probability of N-ERD diagnosis: high recurrence of NP, loss of smell, moderate to severe asthma, intolerance of alcohol, and blood eosinophilia.
If answers at step 2 and 3 are positive: N-ERD can be diagnosed with high probability.
If answer to one of the above questions is negative or uncertain, go to steps 4-6.
Step 4. When the history of respiratory symptoms is not convincing, ask about non-respiratory symptoms after intake of the NSAIDs and check other potential triggers of reported reactions.
F I G U R E 2 Algorithm for diagnosis of N-ERD (description in the text)
BOX 3 Contraindications for aspirin challenge tests
Oral or inhalation aspirin challenge tests:
• • pregnancy, and • current treatment with β-receptor blocker.
Nasal challenge test:
• pathology of the nasal cavity which interferes with nasal challenge and
• upper respiratory tract infection within 4 weeks prior to the test.
Step 5. Exclude/confirm the presence of CRS (ENT consultation; sinus imaging) and asthma (respiratory function test, assessment of non-specific bronchial hyper reactivity).
Step 6. Perform oral, inhaled or intranasal aspirin challenge
Step 7a. If aspirin challenge is positive → N-ERD is diagnosed, go to management
Step 7b. If aspirin challenge is negative → N-ERD can be excluded with high probability; follow-up the patient if necessary (*) (*) if aspirin challenge is negative, but there is concern that concomitant medications (leukotriene modifier drugs or monoclonal antibodies) might have led to a false negative challenge → consider withholding concomitant medications and repeat the challenge. However, several distinct pathophysiological mechanisms associated with this syndrome suggest that more specific treatments referring to syndrome-specific pathways/targets should be considered in the future.
| MANAGEMENT OF PATIENTS WITH N -ERD
| Management of NSAID hypersensitivity
The management options are essentially based on strict avoidance of the culprit drug and cross-reactive drugs. Patient's education is important, since NSAIDs respiratory symptoms are not limited to a specific drug, but they may appear after the intake of other, crossreacting NSAIDs as well.
Statements and recommendations 2,47-51
• The likelihood of cross-reactivity between NSAIDs in patients with N-ERD is directly related to their power of COX-1 inhibition (Grade 1A).
• A patient must avoid not only the single drug responsible for his/her symptoms, but also all the other molecules which are strong COX-1 inhibitors ( Table 1 ) (Grade 1A).
• Selective COX-2 inhibitors (celecoxib and etoricoxib) are well tolerated by most N-ERD patients (Grade 2B)
• NSAIDs with weak inhibitory action toward COX-1 (i.e, paracetamol <1000 mg) (Grade 2B) and preferential COX-2 inhibitors (i.e, nimesulide and meloxicam)(Grade 1B), given at pharmacological doses, do not usually cross-react with other NSAIDs.
• Tolerance tests with alternative NSAID should be performed in the office before the drug is prescribed (Grade 4B).
• Although low salicylate diet has been reported to significantly improve sinonasal symptoms, quality of life and endoscopic scores, as well as asthma control in N-ERD patients, at present stage of evidence additional studies are needed to confirm its efficacy (Grade 4D).
• Alcohol avoidance should be advised to N-ERD patients (Grade 3C).
• Written information, including lists of potentially cross-reactive and alternative safe medications, should be always provided to N-ERD patients (Grade 4D).
• Patients should carry with them information about their drug hypersensitivity (Grade 4D).
| Management of asthma
In most N-ERD patients standard, step-wise approach to asthma treatment following GINA/US guidelines is effective. Combination therapy with inhaled corticosteroid and long acting beta-2 agonists is sufficient to control asthma in the majority of N-ERD patients; however, in some patients more specific measures should be considered.
Overexpression of 5-LO pathways of AA and overproduction of cysteinyl leukotrienes seem to provide a rational for treatment with leukotriene-modifying drugs (LTMD) in N-ERD patients. 52, 53 Prospective, placebo-controlled studies with montelukast 54 and zileuton 55 have both shown efficacy in N-ERD patients as measured by improved respiratory function, decreased use of rescue inhalers, and an increase in asthma quality-of-life measures. Zileuton may have superior efficacy in N-ERD since it blocks all leukotriene production by virtue of 5-LO inhibition, and based on patients' survey data, zileuton had a higher benefit in N-ERD patients. 56 A critical question is if LTMD are more effective in N-ERD patients as compared to NSAIDs-tolerant asthmatics, which could justify to consider LTMD as drug of choice in these patients. Two controlled studies compared efficacy of montelukast in the treatment of N-ERD and NSAIDs-tolerant patients, and both failed to show its superiority in N-ERD patients. 57, 58 Biologicals seem to be promising agents for the treatment of N-ERD, especially in difficult to treat asthmatics. N-ERD patients can benefit from the treatment with omalizumab, and its effectiveness has been described in several case reports. In a recent study of 21 patients with history of bronchial reactions after NSAIDs intake, 12 months therapy with omalizumab resulted in a reduction of the number of exacerbation and ameliorated respiratory symptoms which were accompanied by a significant reduction in urinary LTE 4 and PGD 2 M levels. 59 Biologicals targeting eosinophilic inflammation (mepolizumab, reslizumab, and benralizumab), which is typical for most N-ERD patients, could be potentially beneficial. Mepolizumab was shown recently to be effective in nasal polyposis with co-morbid asthma in a trial in which N-ERD subjects were included. 60 Statements and Recommendations [54] [55] [56] [57] [58] [59] • The management for the N-ERD patient should be individualized;
however, the severity of asthma should be assessed early in the disease course and considered in treatment decisions.
• Standard, step-wise approach to the treatment of bronchial asthma symptoms in N-ERD patients is recommended. Combination therapy with inhaled corticosteroid and long acting beta2
agonists is effective as initial treatment for most N-ERD patients.
For patients with more severe disease, oral corticosteroids should be implemented (Grade 4 D).
• The addition of a LTMD is effective in ameliorating asthma symptoms in N-ERD patients (Grade 1 A); thus, anti-leukotriene drugs can be considered as add-on therapy (Grade 1 A).
• LTMD are not more effective in N-ERD patients as compared to NSAIDs-tolerant asthmatics (Grade 3 B).
• Zileuton seems to be more effective as compared to montelukast in N-ERD patients (Grade 3 D)
• Anti-IgE (omalizumab) seems to be effective in improving asthma control in N-ERD patients with severe asthma (Grade 3 D)
| Management of chronic rhinosinusitis
The management of CRSwNP in patients with N-ERD is similar to that in patients without history of NSAIDs hypersensitivity and should follow international guidelines. 21 However, CRSwNP in patients with N-ERD is more resistant to pharmacological (Grade B) and surgical treatment (Grade B) and concomitant bronchial asthma may complicate the management.
Medical treatment 20, 21, [61] [62] [63] According to current guidelines, medical treatment of CRS should be based on topical corticosteroids with dosing adjusted to the severity of symptoms (Grade A). Short courses of oral steroids (2-3 weeks) may be needed to control severe CRS symptoms and to improve the quality of life (QoL) (Grade A). Nasal saline irrigation, both isotonic and hypertonic, as well as short-term (before surgery) and long-term (after surgery) antibiotics may help to alleviate nasal symptoms (Grade A).
Surgical treatment 20, 21, 64 Sinonasal surgery (polypectomy, functional endoscopic sinus surgery, and/or ethmoidectomy) is reserved for patients with severe or uncontrolled symptoms and for those with inadequate improvement despite intranasal and oral steroid therapy (a picture seen in a significant proportion of N-ERD patients) (Grade C).
Statements and recommendations
• Saline irrigation is important in CRS of all kinds and should be used daily
• Intranasal corticosteroid drops are most effective and constitute the first line of pharmacological treatment for CRS with nasal polyps in patients with N-ERD (Grade A)
• In N-ERD patients, treatment with maximal doses of intranasal corticosteroids is often needed (Grade B)
• Short courses of oral steroids are necessary when maximal doses of intranasal corticosteroids are not able to control CRS severity (Grade A).
• LTMD have moderate effects in relieving nasal symptoms and nasal polyps size in some N-ERD patients (for montelukastGrade B; for zileuton-Grade C).
• LTMD are not more effective in N-ERD patients as compared to
NSAIDs-tolerant patients with CRSwNP (Grade B).
• Macrolides (for 3 months) show a moderate effect on QoL (but not symptoms) in patients with CRSsNP (Grade A). There is no separate evidence for a course of macrolides to be recommended in severe cases of CRSwNP in N-ERD (Grade D).
• Anti-IgE/omalizumab is equally effective in N-ERD and NSAIDstolerant patients in relieving nasal symptoms (Grade A) but without evidence of preventing polyp recurrence after surgery (Grade D).
• • Endoscopic sinus surgery may reduce bronchial symptoms (Grade D) and the requirement for asthma medications (Grade D) in N-ERD patients.
• N-ERD patients respond less well to surgical interventions and are more likely to undergo repeated interventions as compared to NSAIDs-tolerant subjects (Grade D).
• • For nasal surgery, N-ERD patients should be referred to the most experienced ENT centers (Grade D).
• Follow-up and medications, including nasal and oral corticosteroids, are recommended after surgery (Grade A).
| Aspirin treatment after desensitization (ATAD)
Following the original report of Stevenson et al, 65 it has been well documented that aspirin given after desensitization may improve CRS and asthma course in N-ERD patients. The efficacy of ATAD KOWALSKI ET AL.
has been confirmed in observational studies and in placebo-controlled double-blind trials. [66] [67] [68] Protocols for desensitization are usually extension of ASA-provocation protocols; however, a "silent" desensitization (i.e, without evoking adverse reaction) is possible. 69, 70 Patients for ATAD should be carefully selected and monitored during treatment to assess the efficacy and to reduce the prevalence of adverse effects associated with aspirin intake.
Statements and recommendations [65] [66] [67] [68] • Aspirin treatment after desensitization is an option in the management of patients with N-ERD (Grade 1B) (Box 4)
• Desensitization procedure can be performed in both outpatient and hospital setting and should be supervised by experienced physician (Grade 4D)
• To secure safety and effectiveness of desensitization, the panel recommends that one of well-established protocols is followed with gradual dose increase with at least 90-120 min intervals between doses (Grade 4 D) ( Table 2) • In the majority of N-ERD patients, ATAD is associated with a • In a subset of N-ERD patients, ATAD may result in decreased asthma symptoms and improved asthma control (Grade 1 B)
• The overall effect of ATAD on asthma seems to be less favorable as compared to the effect on the course of CRS (Grade 4 D)
• Effective oral maintenance dose of aspirin ranges from 300 to 1300 mg (Grade 3 C)
• ATAD is associated with adverse effects (mostly gastrointestinal), and the incidence of adverse symptoms related to aspirin intake ranges from 0% to 34%.
• In order to reduce the prevalence of adverse effects associated with aspirin treatment, appropriate preventive measures (Helicobacter pylori eradication, PPI, and H 2 blockers) should be intro- metabolite that accompanied patient-reported improvement in respiratory symptoms. 59 Mepolizumab, an anti-IL-5 monoclonal antibody that has been approved for severe eosinophilic asthma, has been shown in two studies to decrease nasal polyposis, 60, 71 and dupilumab, the IL-4Rα antagonist that blocks both IL-4 and IL-13 signaling, has also been shown to decrease nasal polyps burden. 61 New biologicals may provide substantial benefit to patients with N-ERD and eosinophilic nasal polyposis.
Recent work suggests that the innate immune response pathways (cytokines IL-33 and TSLP) may be involved in N-ERD pathogenesis and research efforts targeting these novel innate pathways should be explored. 30, 72 Inhibition of other recently described putative leukotriene receptors, like GPR99, 73 or the PGD2 receptor CRTH2, is also potential future targets for N-ERD-directed therapeutics.
| CONCLUSION S AND UN MET N EEDS
The expert panel believes that the current document, by summarizing up-to-date knowledge, and proposing practical recommendations for the diagnosis and treatment of N-ERD will help physicians to offer comprehensive and effective management for a patient with this complex disorder. However, the panelists realize that despite • Development and testing of novel treatment modalities, based on endotype/sub-endotype-driven approaches
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